Resolian Strengthens Its Team: Rob Stachlewitz Named CEO, Honggang Bi Appointed As Chairman

Resolian, a top-tier global partner in bioanalytical and analytical sciences for drug development and multi-regional clinical trials, has announced key leadership appointments to support its ongoing global expansion. Rob Stachlewitz will assume the role of Chief Executive Officer, succeeding Pat Bennett, who will now serve as the Chief Business Officer and President of Scientific Affairs, a position designed to enhance Resolian’s strategic growth. Additionally, Honggang Bi has been appointed as Chairman by the board.

Driven by investment from Boston’s Ampersand Capital Partners and KKR’s Health Care Strategic Growth initiative, Resolian has achieved significant growth in recent years, establishing itself as a leading bioanalytical contract research organization (CRO). This expansion included the acquisition of Alliance Pharma, Inc. in Malvern, PA; the addition of UK-based Drug Development Solutions in mid-2022; the launch of a high-tech bioanalytical lab in Brisbane, Australia at the end of 2022; and the acquisition of China-based Denali MedPharm in late 2023, extending its presence across four continents.

Rob Stachlewitz steps into the role of CEO at Resolian, bringing a wealth of industry experience and a strong record of leadership. Previously, as Corporate Vice President and General Manager at Charles River, Rob managed operations at the company’s largest site. With 15 years dedicated to pharmaceutical R&D, including significant positions at Boehringer Ingelheim, Abbott Laboratories, and Procter & Gamble, he is well-equipped to lead Resolian into its next chapter. Under Rob’s leadership, the company will focus on expanding its global reach and strengthening operational capabilities to drive continued growth and innovation.

Honggang Bi. Newly-appointed Chairman Honggang Bi posesses a more than 30 year illustrious career with Pfizer, Covance and Labcorp, leading their drug development operations across multiple geographies, said in a statement, "It's an honor to be appointed Chairman of Resolian. I am excited to work alongside Rob, Pat, the Ampersand and KKR teams, and our nearly 500 dedicated global employees. Resolian is an innovative, global, bioanalytical and analytical CRO. I am confident we have the leadership, vision and dedicated quality-driven team to execute our clients' therapeutic programs.”

Honggang Bi added that Rob, a respected scientific leader, holds a PhD from UNC Chapel Hill and a B.S. from Michigan State University. With over 30 publications, he has guided numerous drugs through development, said in a statement, "With Rob's extensive background shepherding life science businesses and teams on a global scale, we are confident that he will lead Resolian to new heights as we continue to expand our bioanalytical operations.”

Dave Patteson, Partner, Ampersand Capital Partners, stated, "We are incredibly grateful for Pat's leadership during a pivotal time in Resolian's history. As he transitions into his new role, Pat will continue to make critical contributions to Resolian's future growth and innovation. The combined leadership of Honggang, Rob and Pat is unrivaled in the bioanalytical CRO industry. The Resolian team will provide industry leading bioanalytical services to clients for their drug development projects across all major geographies.”

Pat Bennett, who has been at the helm of Resolian for almost three years, has played a crucial role in strategically guiding the organization during a period of significant change and growth. His leadership has successfully aligned operations and facilitated global expansion. As the Chief Business Officer and President of Scientific Affairs, Pat will concentrate on developing new service offerings and strengthening customer relationships, drawing on his extensive 30+ years of experience in bioanalytical sciences and business development. Additionally, he will manage key functions to promote collaboration and synergies within the Resolian team.